{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:08:40Z","timestamp":1791144520034,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019476","name":"Siriraj Foundation","doi-asserted-by":"publisher","award":["D-003658"],"award-info":[{"award-number":["D-003658"]}],"id":[{"id":"10.13039\/100019476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["BRG5980006"],"award-info":[{"award-number":["BRG5980006"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N41A640162"],"award-info":[{"award-number":["N41A640162"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.117964","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:02:51Z","timestamp":1742284971000},"page":"117964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Vorinostat restores iNKT cell functionality in aggressive cholangiocarcinoma"],"prefix":"10.1016","volume":"186","author":[{"given":"Khin Su Su","family":"Htwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitipong","family":"Soontrapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunisa","family":"Prasopporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-9760","authenticated-orcid":false,"given":"Porncheera","family":"Chusorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Jirawatnotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6103","authenticated-orcid":false,"given":"Somponnat","family":"Sampattavanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-0997","authenticated-orcid":false,"given":"Adisak","family":"Wongkajornsilp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2025.117964_bib1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.117964_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117964_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2025.117964_bib4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2025.117964_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/652875","article-title":"Antitumor responses of invariant natural killer T cells","volume":"2015","author":"Altman","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.117964_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","article-title":"The regulatory role of invariant NKT cells in tumor immunity","volume":"3","author":"McEwen-Smith","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117964_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1601399","article-title":"Type II NKT cells and their emerging role in health and disease","volume":"198","author":"Dhodapkar","year":"2017","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2217\/1750743X.1.1.73","article-title":"Invariant natural killer T cell-based immunotherapy for cancer","volume":"1","author":"Motohashi","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2025.117964_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The role of natural killer T cells in cancer-A phenotypical and functional approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117964_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.117964_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.995562","article-title":"Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice","volume":"4","author":"Gebremeskel","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.117964_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117964_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113909","article-title":"License to kill: When iNKT cells are granted the use of lethal cytotoxicity","volume":"21","author":"Diaz-Basabe","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.117964_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061329","article-title":"Targeting natural killer T cells in solid malignancies","volume":"10","author":"Ingram","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.117964_bib16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3389\/fimmu.2017.01355","article-title":"Invariant natural killer T cells in immune regulation of blood cancers: harnessing their potential in immunotherapies","volume":"8","author":"Lam","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117964_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.leukres.2004.06.005","article-title":"The peripheral blood Valpha24+\u2009NKT cell numbers decrease in patients with haematopoietic malignancy","volume":"29","author":"Yoneda","year":"2005","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.117964_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/epi.19373","article-title":"CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1\/2 and activation of Sp1","volume":"7","author":"Yang","year":"2012","journal-title":"Epigenetics"},{"issue":"7","key":"10.1016\/j.biopha.2025.117964_bib19","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Tahir","year":"2001","journal-title":"J. Immunol."},{"issue":"42","key":"10.1016\/j.biopha.2025.117964_bib20","doi-asserted-by":"crossref","first-page":"17847","DOI":"10.1073\/pnas.0904078106","article-title":"Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1","volume":"106","author":"Kojo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.biopha.2025.117964_bib21","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.1073\/pnas.122636199","article-title":"Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells","volume":"99","author":"Sriram","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcb.22549","article-title":"TRAIL\/TRAIL-R in hematologic malignancies","volume":"110","author":"Testa","year":"2010","journal-title":"J. Cell Biochem."},{"issue":"10","key":"10.1016\/j.biopha.2025.117964_bib23","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36468-8","article-title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","volume":"13","author":"Balasko","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.117964_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173057","article-title":"Vorinostat upregulates MICA via the PI3K\/Akt pathway to enhance the ability of natural killer cells to kill tumor cells","volume":"875","author":"Xia","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.biopha.2025.117964_bib27","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.7150\/jca.34471","article-title":"Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2025.117964_bib28","article-title":"A new trend in cancer treatment: the combination of epigenetics and immunotherapy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.117964_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021632","article-title":"Corrigendum: combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma","volume":"12","author":"Prasopporn","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.117964_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105182","article-title":"Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma","volume":"25","author":"Jamnongsong","year":"2022","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.biopha.2025.117964_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1428156","article-title":"Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells","volume":"7","author":"Dockry","year":"2018","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.biopha.2025.117964_bib32","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1158\/1078-0432.CCR-08-1468","article-title":"Ascites specific inhibition of CD1d-mediated activation of natural killer T cells","volume":"14","author":"Webb","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.117964_bib33","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2025.117964_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020702","article-title":"CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis","volume":"6","author":"Hix","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.117964_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12943-021-01366-y","article-title":"Novel induction of CD40 expression by tumor cells with RAS\/RAF\/PI3K pathway inhibition augments response to checkpoint blockade","volume":"20","author":"Yan","year":"2021","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2025.117964_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213998","article-title":"Integrative and comprehensive pan-cancer analysis of lymphocyte-specific protein tyrosine kinase in human tumors","volume":"23","author":"Han","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.117964_bib37","first-page":"11","article-title":"Emerging role of Toll-like receptor 4 in hepatocellular carcinoma","volume":"2","author":"Yang","year":"2015","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"12","key":"10.1016\/j.biopha.2025.117964_bib38","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.4049\/jimmunol.168.12.6041","article-title":"The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24","volume":"168","author":"Caudell","year":"2002","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.biopha.2025.117964_bib39","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1158\/0008-5472.CAN-13-0890","article-title":"An intact immune system is required for the anticancer activities of histone deacetylase inhibitors","volume":"73","author":"West","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.117964_bib40","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.117964_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/srep21678","article-title":"Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma","volume":"6","author":"Ritter","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.117964_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pros.24479","article-title":"Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH","volume":"83","author":"Chang","year":"2023","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/j.biopha.2025.117964_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184700","article-title":"Vorinostat (SAHA) and breast cancer: an overview","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2025.117964_bib44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"Wilson","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2025.117964_bib45","article-title":"Overcome drug resistance in cholangiocarcinoma: new insight into mechanisms and refining the preclinical experiment models","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.117964_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217116","article-title":"Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment","volume":"598","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.biopha.2025.117964_bib47","first-page":"349","article-title":"Trichostatin A sensitizes hepatocellular carcinoma cells to enhanced NK cell-mediated killing by regulating immune-related genes","volume":"14","author":"Shin","year":"2017","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.biopha.2025.117964_bib48","article-title":"Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117964_bib49","first-page":"1351","article-title":"The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells","volume":"33","author":"Horing","year":"2013","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.117964_bib50","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00262-016-1900-z","article-title":"Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma","volume":"65","author":"Tiper","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2025.117964_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701671","article-title":"Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat","volume":"12","author":"Afolabi","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:58:58Z","timestamp":1781823538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"alternative-id":["S0753332225001581"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117964","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vorinostat restores iNKT cell functionality in aggressive cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117964"}}